Atorvastatin-induced downregulation of survivin and vascular smooth muscle cell apoptosis: A causal relationship in restenosis?

Cardiovascular Drugs and Therapy

Volumn 21, Issue 3, 2007, Pages 141-144

  Erl, Wolfgang ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN 2; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; SURVIVIN; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; DRUG ELUTING STENT; DRUG MECHANISM; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; IN-STENT RESTENOSIS; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SECONDARY PREVENTION; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

ANIMALS; APOPTOSIS; CORONARY RESTENOSIS; DOWN-REGULATION; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROTUBULE-ASSOCIATED PROTEINS; MUSCLE, SMOOTH, VASCULAR; NEOPLASM PROTEINS; PYRROLES;

EID: 34249298721     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6028-0     Document Type: Editorial

References (27)

1. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-62.
2. Kockx MM, Knaapen WM. The role of apoptosis in vascular disease. J Pathol 2000;190:267-80.
3. Liao JK. Beyond lipid lowering: the role of statins in vascular protection. Int J Cardiol 2002;86:5-18.
4. Gotto AM Jr, Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol 2001;12:391-4.
5. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998;83:490-500.
6. Erl W. Statin-induced vascular smooth muscle cell apoptosis: a possible role in the prevention of restenosis? Curr Drug Targets Cardiovasc Haematol Disord 2005;5:135-44.
7. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002;161:17-26.
8. Igarashi M, Yamaguchi H, Hirata A, Tsuchiya H, Ohnuma H, Tominaga M, et al. Mechanisms of inhibitory effects of cerivastatin on rat vascular smooth muscle cell growth. J Cardiovasc Pharmacol 2002;40:277-87.
9. Fouty BW, Rodman DM. Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway. Circ Res 2003;92:501-9.
10. WAF1/Cip1 in human vascular smooth muscle cells: influence on protein phosphorylation, cell cycle, induction of apoptosis, and growth inhibition. Int J Mol Med 1999;3:63-8.
11. Kannan K, Amariglio N, Rechavi G, Jakob-Hirsch J, Kela I, Kaminski N, et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 2001;20:2225-34.
12. WAF1/CIP1 pathway. Biochem Biophys Res Commun 2003;311:546-52.
13. Erl W, Hristov M, Neureuter M, Yan ZQ, Hansson GK, Weber PC. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis 2003;169:251-8.
14. Orlandi A, Francesconi A, Cocchia D, Corsini A, Spagnoli LG. Phenotypic heterogeneity influences apoptotic susceptibility to retinoic acid and cis-platinum of rat arterial smooth muscle cells in vitro: implications for the evolution of experimental intimal thickening. Arterioscler Thromb Vasc Biol 2001;21:1118-23.
15. 2-induced cytotoxicity in "epithelioid" smooth muscle cells: implications for neointimal regression. Arterioscler Thromb Vasc Biol 2000;20:1473-9.
16. Lau HK. Cytotoxicity of nitric oxide donors in smooth muscle cells is dependent on phenotype, and mainly due to apoptosis. Atherosclerosis 2003;166:223-32.
17. Xu et al. Cardiovasc Drugs Ther 2007.
18. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;8:917-21.
19. Blanc-Brude OP, Yu J, Simosa H, Conte MS, Sessa WC, Altieri DC. Inhibitor of apoptosis protein survivin regulates vascular injury. Nat Med 2002;9:987-94.
20. Blanc-Brude OP, Teissier E, Castier Y, Lesèche G, Bijnens AP, Daemen M, et al. IAP Survivin regulates atherosclerotic macrophage survival. Arterioscler Thromb Vasc Biol 2007;27:901-7.
21. Moran EP, Agrawal DK. Increased expression of inhibitor of apoptosis proteins in atherosclerotic plaques of symptomatic patients with carotid stenosis. Exp Mol Pathol 2007; in press.
22. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926-33.
23. Zeiffer U, Schober A, Lietz M, Liehn EA, Erl W, Emans N, et al. Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. Circ Res 2004;94:776-84.
24. Erl W, Hansson GK, de Martin R, Draude G, Weber KS, Weber C. Nuclear factor-κB regulates induction of apoptosis and inhibitor of apoptosis protein-1 expression in vascular smooth muscle cells. Circ Res 1999;84:668-77.
25. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.
26. Jaschke B, Michaelis C, Milz S, Vogeser M, Mund T, Hengst L, et al. Local statin therapy differentially interferes with smooth muscle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform. Cardiovasc Res 2005;68:483-92.
27. Siegel-Axel DI. Cerivastatin: a cellular and molecular drug for the future? Cell Mol Life Sci 2003;60:144-64.